Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Press release

Redeye: Acconeer - H2 2025 critical for confidence in targets

Acconeer

Redeye states that Acconeer's Q2 2025 report fell short of its expectations for both sales and EBITDA. A redeeming feature of an otherwise challenging quarter was a decent order intake across key verticals. Redeye believes H2 2025 will be a critical juncture for the share. Redeye posits that A111 sales must increase to continue inventory digestion, while a significant portion of the 2027 net sales target exceeding SEK300m is contingent on a successful A2 launch. From this perspective, H2 2025 will be important for news flow. Redeye has calibrated its estimates and revised its fair value range.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments


Acconeer - H2 2025 critical for confidence in targets

Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.